Last 12 months
Inside the activity.
0 purchase rows · 54 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 5 |
| May 2026 | 0 | 12 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
|
GrantPerformance Rights · Derivative | 1,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005917 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,975 Underlying: Common Stock · 1,975 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 13,300 | $0.00 Strike: $88.78 | $0.00 |
DisclosureSEC source: 0001225208-23-005917 · doc4.xml · derivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2030-05-10 F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
|
GrantCommon Stock | 1,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005917 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,664.7785 F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
Zovighian Bernard JPresident
|
GrantPerformance Rights · Derivative | 28,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005916 · doc4.xml · derivative · entry 3 Zovighian Bernard J · CIK 0001665141 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,150 Underlying: Common Stock · 28,150 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
Zovighian Bernard JPresident
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 173,700 | $0.00 Strike: $88.78 | $0.00 |
DisclosureSEC source: 0001225208-23-005916 · doc4.xml · derivative · entry 2 Zovighian Bernard J · CIK 0001665141 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,700 Underlying: Common Stock · 173,700 shares Expires 2030-05-10 F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
Zovighian Bernard JPresident
|
GrantCommon Stock | 22,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005916 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,552.8735 F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantPerformance Rights · Derivative | 8,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005918 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,025 Underlying: Common Stock · 8,025 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 54,200 | $0.00 Strike: $88.78 | $0.00 |
DisclosureSEC source: 0001225208-23-005918 · doc4.xml · derivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,200 Underlying: Common Stock · 54,200 shares Expires 2030-05-10 F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantCommon Stock | 6,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005918 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,502.6931 F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
Szyman Catherine M.CVP, Critical Care
|
GrantPerformance Rights · Derivative | 8,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005915 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,175 Underlying: Common Stock · 8,175 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
Szyman Catherine M.CVP, Critical Care
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 50,400 | $0.00 Strike: $88.78 | $0.00 |
DisclosureSEC source: 0001225208-23-005915 · doc4.xml · derivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,400 Underlying: Common Stock · 50,400 shares Expires 2023-05-10 F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
Szyman Catherine M.CVP, Critical Care
|
GrantCommon Stock | 6,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005915 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,055.7795 F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
Chopra DaveenCVP, TMTT
|
GrantPerformance Rights · Derivative | 8,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005914 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,100 Underlying: Common Stock · 8,100 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
Chopra DaveenCVP, TMTT
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 49,900 | $0.00 Strike: $88.78 | $0.00 |
DisclosureSEC source: 0001225208-23-005914 · doc4.xml · derivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,900 Underlying: Common Stock · 49,900 shares Expires 2030-05-10 F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC |
Chopra DaveenCVP, TMTT
|
GrantCommon Stock | 6,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005914 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,450 F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:24 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
GrantPerformance Rights · Derivative | 11,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005913 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,825 Underlying: Common Stock · 11,825 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:24 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 72,900 | $0.00 Strike: $88.78 | $0.00 |
DisclosureSEC source: 0001225208-23-005913 · doc4.xml · derivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,900 Underlying: Common Stock · 72,900 shares Expires 2030-05-10 F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:24 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
GrantCommon Stock | 9,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005913 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,744 F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:15 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 2,500 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-005756 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 2,500 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:15 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
SaleCommon Stock | 2,500 | $89.22 | $223,050.00 |
DisclosureSEC source: 0001225208-23-005756 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,077.6931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:15 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionCommon Stock | 2,500 | $36.75 | $91,875.00 |
DisclosureSEC source: 0001225208-23-005756 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,577.6931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2023. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 80,700 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-23-005755 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,700 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
SaleCommon Stock | 64,119 | $88.36 | $5,665,618.96 |
DisclosureSEC source: 0001225208-23-005755 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,294 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $87.89 to $88.88 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
SaleCommon Stock | 16,581 | $89.22 | $1,479,385.01 |
DisclosureSEC source: 0001225208-23-005755 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,413 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $88.89 to $89.44 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 80,700 | $35.20 | $2,840,373.69 |
DisclosureSEC source: 0001225208-23-005755 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,375 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-23-005754 · doc4.xml · derivative · entry 9 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,375 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005754 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Living Trust Disclosed balance after: 3,616,922 Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 13,891 | $88.29 | $1,226,436.39 |
DisclosureSEC source: 0001225208-23-005754 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,724.82 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $87.83 to $88.83 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005754 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,615.82 Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 5,984 | $88.94 | $532,216.96 |
DisclosureSEC source: 0001225208-23-005754 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,115.82 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $88.84 to $89.25 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 29,375 | $35.20 | $1,033,903.06 |
DisclosureSEC source: 0001225208-23-005754 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,099.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. Read SEC document |
| May 09, 2023 Filed May 9, 2023 23:48 UTC |
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,640 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-23-005617 · doc4.xml · derivative · entry 7 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,640 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2023 Filed May 9, 2023 23:48 UTC |
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
|
SaleCommon Stock | 6,640 | $88.68 | $588,835.20 |
DisclosureSEC source: 0001225208-23-005617 · doc4.xml · nonDerivative · entry 5 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,089.7785 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022. Read SEC document |
| May 09, 2023 Filed May 9, 2023 23:48 UTC |
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
|
Exercise / conversionCommon Stock | 6,640 | $35.20 | $233,706.09 |
DisclosureSEC source: 0001225208-23-005617 · doc4.xml · nonDerivative · entry 4 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,729.7785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022. Read SEC document |
| May 09, 2023 Filed May 9, 2023 23:48 UTC |
Szyman Catherine M.CVP, Critical Care
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 75,600 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-23-005616 · doc4.xml · derivative · entry 7 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,600 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2023 Filed May 9, 2023 23:48 UTC |
Szyman Catherine M.CVP, Critical Care
|
SaleCommon Stock | 75,600 | $88.94 | $6,724,234.44 |
DisclosureSEC source: 0001225208-23-005616 · doc4.xml · nonDerivative · entry 5 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,530.7795 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $88.35 to $89.14 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2023 Filed May 9, 2023 23:48 UTC |
Szyman Catherine M.CVP, Critical Care
|
Exercise / conversionCommon Stock | 75,600 | $35.20 | $2,660,870.52 |
DisclosureSEC source: 0001225208-23-005616 · doc4.xml · nonDerivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,130.7795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023. Read SEC document |
| May 08, 2023 Filed May 9, 2023 01:54 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 1,399 | $88.74 | $124,147.26 |
DisclosureSEC source: 0001225208-23-005593 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,624.6931 Read SEC document |
| May 08, 2023 Filed May 10, 2023 00:53 UTC |
Zovighian Bernard JPresident
|
Tax withholdingCommon Stock | 1,433 | $88.74 | $127,164.42 |
DisclosureSEC source: 0001225208-23-005622 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,027.8735 Read SEC document |
| May 08, 2023 Filed May 9, 2023 23:50 UTC |
SELLERS ROBERT W.A.SVP, Corporate Controller
|
Tax withholdingCommon Stock | 161 | $88.74 | $14,287.14 |
DisclosureSEC source: 0001225208-23-005621 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,235.7904 Read SEC document |
| May 08, 2023 Filed May 9, 2023 23:50 UTC |
Wood Larry LCVP & Grp President TAVR & SSH
|
Tax withholdingCommon Stock | 1,472 | $88.74 | $130,625.28 |
DisclosureSEC source: 0001225208-23-005620 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP & Grp President TAVR & SSH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,310.7137 Read SEC document |
| May 08, 2023 Filed May 9, 2023 23:49 UTC |
Chopra DaveenCVP, TMTT
|
Tax withholdingCommon Stock | 967 | $88.74 | $85,811.58 |
DisclosureSEC source: 0001225208-23-005619 · doc4.xml · nonDerivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,975 Read SEC document |
| May 08, 2023 Filed May 9, 2023 23:48 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 1,674 | $88.74 | $148,550.76 |
DisclosureSEC source: 0001225208-23-005618 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,294 Read SEC document |
| May 08, 2023 Filed May 9, 2023 23:48 UTC |
Lemercier Jean-Luc MCVP, EMEACLA and JAPAC
|
Tax withholdingCommon Stock | 104 | $88.74 | $9,228.96 |
DisclosureSEC source: 0001225208-23-005617 · doc4.xml · nonDerivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,089.7785 Read SEC document |
| May 08, 2023 Filed May 9, 2023 23:48 UTC |
Szyman Catherine M.CVP, Critical Care
|
Tax withholdingCommon Stock | 1,376 | $88.74 | $122,106.24 |
DisclosureSEC source: 0001225208-23-005616 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,530.7795 Read SEC document |
| May 07, 2023 Filed May 9, 2023 01:54 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionPerformance Rights · Derivative | 4,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005593 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,308 Underlying: Common Stock · 4,767 shares Expires 2027-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 07, 2023 Filed May 9, 2023 01:54 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 2,968 | $88.74 | $263,380.32 |
DisclosureSEC source: 0001225208-23-005593 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,023.6931 Read SEC document |
| May 07, 2023 Filed May 9, 2023 01:54 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionCommon Stock | 4,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005593 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,991.6931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 07, 2023 Filed May 10, 2023 00:53 UTC |
Zovighian Bernard JPresident
|
Exercise / conversionPerformance Rights · Derivative | 5,003 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005622 · doc4.xml · derivative · entry 4 Zovighian Bernard J · CIK 0001665141 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,372 Underlying: Common Stock · 5,003 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. F1 · derivative.expiration_date: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 07, 2023 Filed May 10, 2023 00:53 UTC |
Zovighian Bernard JPresident
|
Tax withholdingCommon Stock | 2,323 | $88.74 | $206,143.02 |
DisclosureSEC source: 0001225208-23-005622 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,460.8735 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.